Annexin Pharmaceuticals AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 14.55 million compared to SEK 10.12 million a year ago. Basic loss per share from continuing operations was SEK 0.09 compared to SEK 0.07 a year ago.
For the full year, net loss was SEK 44.05 million compared to SEK 40.73 million a year ago. Basic loss per share from continuing operations was SEK 0.26 compared to SEK 0.28 a year ago.